300858 科拓生物
2026/06 - 中期
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入169,5053.77%365,923302,793299,242369,165
减:营业总成本147,45922.98%270,341211,440209,601256,815
    其中:营业成本89,6878.17%177,463126,411135,910177,290
               财务费用(4,301)-56.79%(19,713)(24,475)(23,455)(3,187)
               资产减值损失----(262)------
公允价值变动收益2,227132.94%1,6202,0131,262168
投资收益4,051211.85%2,1813,5786,1229,173
    其中:对联营企业和合营企业的投资收益2,432-4,229.23%466317(718)(416)
营业利润27,252-45.36%104,603109,463102,602127,577
利润总额27,254-45.36%103,830108,828102,041125,656
减:所得税费用2,157-75.14%9,31114,4728,56115,764
净利润25,097-39.09%94,51994,35693,480109,891
减:非控股权益------------
股东净利润25,097-39.09%94,51994,35693,480109,891

市场价值指针
每股收益 (元) *0.100-37.50%0.3600.3600.3500.490
每股派息 (元) *----0.1000.1500.1500.300
每股净资产 (元) *6.8010.04%6.9946.7926.57711.392
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容